首页 | 本学科首页   官方微博 | 高级检索  
     

紫杉醇联合化疗对中晚期胃癌的临床疗效观察及抗癌作用机制的探讨
引用本文:许成贵. 紫杉醇联合化疗对中晚期胃癌的临床疗效观察及抗癌作用机制的探讨[J]. 现代保健, 2013, 0(16): 34-36
作者姓名:许成贵
作者单位:山东省寿光市人民医院,山东寿光262700
摘    要:目的:探讨紫杉醇对中晚期胃癌的临床疗效及其抗肿瘤机制。方法:将68例中晚期胃癌患者随机分为观察组和对照组,对照组给予PFL化疗方案,观察组在此基础上加用紫杉醇,观察两组的临床疗效和不良反应发生率。结果:观察组总有效率为61.8%,对照组总有效率为38.2%,两组临床疗效差异有统计学意义(P〈0.05),而两组不良反应发生率差异无统计学意义(P〉0.05).结论:紫杉醇应用于中晚期胃癌治疗,临床疗效显著,不良反应发生率无变化。

关 键 词:紫杉醇  中晚期胃癌  临床观察

The Mechanism and the Clinical Efficacy of Paclitaxel Combined with Chemotherapy in the Treatment of Advanced Gastric Cancer
Affiliation:XU Cheng-gni.
Abstract:Objective: To explore the clinical efficacy of paclitaxel in the treatment of advanced gastric cancer and the mechanism.Method: 68 cases of advanced gastric cancer were randomly divided into the observation group and the control group, the control group was given the PFL chemotherapy, the observation group was given paclitaxel on the basis of the control group, the clinical efficacy and safety of the two groups were observed. Result: The total efficiency of the control group was 38.2%, the total efficiency of the observation group was 61.8%, there were significant differences in the clinical efficacy of the groups ( P〈0.05 ) .The adverse reactions of the two groups had no significant difference ( P〉0.05 ) .Conclusion: The clinical efficacy of paclitaxel can significantly improve the treatment of advanced gastric cancer, the incidence of adverse reactions did not change.
Keywords:Paclitaxel  Advanced gastric cancer  Clinical observation
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号